About Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
Industry, Sector and Symbol
Trailing P/E Ratio-1.15866731119073
Forward P/E Ratio-1.99
Sales & Book Value
Annual Sales$9.67 million
Price / Sales16.76
Price / CashN/A
Book Value$2.53 per share
Price / Book1.24
Return on Equity-90.75%
Return on Assets-78.57%
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions
What is Tetraphase Pharmaceuticals' stock symbol?
Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."
How were Tetraphase Pharmaceuticals' earnings last quarter?
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) issued its earnings results on Thursday, March, 8th. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.64) by $0.18. The biopharmaceutical company earned $2.53 million during the quarter, compared to the consensus estimate of $2.26 million. Tetraphase Pharmaceuticals had a negative return on equity of 90.75% and a negative net margin of 1,187.17%. View Tetraphase Pharmaceuticals' Earnings History.
When will Tetraphase Pharmaceuticals make its next earnings announcement?
Where is Tetraphase Pharmaceuticals' stock going? Where will Tetraphase Pharmaceuticals' stock price be in 2018?
8 Wall Street analysts have issued 12 month target prices for Tetraphase Pharmaceuticals' stock. Their predictions range from $3.00 to $11.00. On average, they expect Tetraphase Pharmaceuticals' share price to reach $7.14 in the next twelve months. View Analyst Ratings for Tetraphase Pharmaceuticals.
What are Wall Street analysts saying about Tetraphase Pharmaceuticals stock?
Here are some recent quotes from research analysts about Tetraphase Pharmaceuticals stock:
- 1. Needham & Company LLC analysts commented, "Tetraphase reported 4Q17 financial results yesterday after market close and we spoke w/ mgmt for an update. As a reminder, the company announced last month that the IV eravacycline Phase 3 IGNITE3 trial in complicated Urinary Tract Infections (cUTI) missed the primary endpoint. We do not expect the company to continue development in cUTI, nor to pursue development of an oral formulation of the drug. IV eravacycline is under review for complicated Intra- Abdominal Infections (cIAI) in both the U.S. and E.U. We expect approval by the 8/28/18 PDUFA date in the U.S. and in 2H18 in Europe. Maintain HOLD rating, based on concerns around commercial potential for lead asset IV eravacycline." (3/7/2018)
- 2. HC Wainwright analysts commented, "a Highly Favorable Risk/Reward; Affirm Buy Stock Data 02/05/2018 Price $5.19 Exchange NASDAQ Price Target $17.00 52-Week High $9.93 52-Week Low $4.04 Enterprise Value (M) $106.6 Market Cap (M) $268 Public Market Float (M) 37.5 Shares Outstanding (M) 51.6 3 Month Avg Volume 477,304 Short Interest (M) 2.97 Shares Outstanding (M): Figure shown is as of January 24, 2018. Balance Sheet Metrics Cash (M) $161.4 Total Debt (M) $0.0 Total Cash/Share $3.13 Book Value/Share $2.78 Cash (M): Figure shown is as of September 30, 2017. EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.46) (0.79)A (0.56) 2Q (0.47) (0.83)A (0.55) 3Q (0.58) (0.63)A (0.54) 4Q (0.61) (0.60) (0.52) FY (2.11) (2.80) (2.17) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 2.0 1.5A 1.5 2Q 1.2 1.6A 1.0 3Q 0.9 4.1A 1.2 4Q 1.1 2.0 1.5 FY 5.1 9.1 5.2 10 8 6 4 2 FEB- 17 J UN- 17 OCT- 17 FEB- 18 20 15 10 5 0 Vol. (mil) Price cUTI: We believe IGNITE3 will be a solid, clean win." (2/6/2018)
- 3. According to Zacks Investment Research, "Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. " (1/12/2018)
Who are some of Tetraphase Pharmaceuticals' key competitors?
Some companies that are related to Tetraphase Pharmaceuticals include Viralytics (VRACY), MannKind (MNKD), Savara (SVRA), Enzo Biochem (ENZ), Catalyst Biosciences (CBIO), Zymeworks (ZYME), BioSpecifics Technologies (BSTC), Osiris Therapeutics (OSIR), DURECT (DRRX), Arbutus Biopharma (ABUS), Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL), Chromadex (CDXC), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Tocagen (TOCA), NewLink Genetics (NLNK), Bellicum Pharmaceuticals (BLCM) and Fortress Biotech (FBIO).
Who are Tetraphase Pharmaceuticals' key executives?
Tetraphase Pharmaceuticals' management team includes the folowing people:
- Leonard Patrick Gage Ph.D., Chairman of the Board of Directors (Age 74)
- Guy Macdonald, President and Chief Executive Officer, Director (Age 56)
- Kamalam Unninayar, Chief Financial Officer
- Larry Edwards, Chief Operating Officer
- Maria D. Stahl, Senior Vice President, General Counsel (Age 44)
- Larry Tsai M.D, Chief Medical Officer
- Jeffrey A. Chodakewitz M.D., Director (Age 61)
- Geraldine A. Henwood Ph.D., Director (Age 61)
- Garen G. Bohlin, Independent Director (Age 69)
- John G. Freund M.D., Independent Director (Age 63)
Has Tetraphase Pharmaceuticals been receiving favorable news coverage?
News stories about TTPH stock have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tetraphase Pharmaceuticals earned a news impact score of 0.20 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 45.27 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Tetraphase Pharmaceuticals' major shareholders?
Tetraphase Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.84%), Millennium Management LLC (5.26%), Broadfin Capital LLC (1.72%), Renaissance Technologies LLC (1.15%), Candriam Luxembourg S.C.A. (0.98%) and Hudson Bay Capital Management LP (0.97%). Company insiders that own Tetraphase Pharmaceuticals stock include Jacques Dumas and L Patrick Gage. View Institutional Ownership Trends for Tetraphase Pharmaceuticals.
Which major investors are selling Tetraphase Pharmaceuticals stock?
Which major investors are buying Tetraphase Pharmaceuticals stock?
TTPH stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Renaissance Technologies LLC, Deutsche Bank AG, Candriam Luxembourg S.C.A., Virtus Fund Advisers LLC, Two Sigma Investments LP and Paloma Partners Management Co. View Insider Buying and Selling for Tetraphase Pharmaceuticals.
How do I buy shares of Tetraphase Pharmaceuticals?
Shares of TTPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tetraphase Pharmaceuticals' stock price today?
One share of TTPH stock can currently be purchased for approximately $3.14.
How big of a company is Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals has a market capitalization of $158.40 million and generates $9.67 million in revenue each year. The biopharmaceutical company earns $-114,750,000.00 in net income (profit) each year or ($2.71) on an earnings per share basis. Tetraphase Pharmaceuticals employs 78 workers across the globe.
How can I contact Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL STREET SUITE 110, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected]
MarketBeat Community Rating for Tetraphase Pharmaceuticals (TTPH)MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.63||2.71||2.80||2.67|
|Ratings Breakdown: ||0 Sell Rating(s)|
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$7.14||$10.83||$17.00||$11.80|
|Price Target Upside: ||127.48% upside||99.51% upside||191.10% upside||70.03% upside|
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Consensus Price Target History
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Analyst Ratings History
(Data available from 3/20/2016 forward)
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Earnings History and Estimates Chart
Tetraphase Pharmaceuticals (NASDAQ TTPH) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/8/2018||Q4 2017||($0.64)||($0.46)||$2.26 million||$2.53 million||View||N/A|
|11/2/2017||Q3 2017||($0.63)||($0.63)||$1.59 million||$4.10 million||View||N/A|
|8/2/2017||Q2 2017||($0.76)||($0.83)||$1.54 million||$1.59 million||View||N/A|
|5/2/2017||Q1 2017||($0.60)||($0.79)||$1.46 million||$1.48 million||View||N/A|
|3/8/2017||Q4||($0.60)||($0.61)||$1.28 million||$1.09 million||View||Listen|
|11/3/2016||($0.50)||($0.58)||$1.58 million||$0.90 million||View||N/A|
|8/4/2016||Q2||($0.46)||($0.47)||$2.05 million||$1.20 million||View||N/A|
|5/4/2016||Q1||($0.44)||($0.46)||$2.20 million||$2.00 million||View||N/A|
|2/23/2016||Q4||($0.44)||($0.50)||$3.23 million||$2.47 million||View||Listen|
|11/2/2015||Q315||($0.65)||($0.49)||$3.20 million||$2.90 million||View||N/A|
|8/5/2015||Q215||($0.62)||($0.72)||$2.73 million||$3.30 million||View||N/A|
|5/6/2015||Q115||($0.64)||($0.66)||$2.90 million||$3.00 million||View||N/A|
|3/5/2015||($0.54)||($0.69)||$2.74 million||$3.07 million||View||N/A|
|11/10/2014||Q314||($0.56)||($0.55)||$2.86 million||$2.29 million||View||N/A|
|8/12/2014||Q214||($0.54)||($0.71)||$2.79 million||$1.30 million||View||N/A|
|5/12/2014||Q114||($0.45)||($0.53)||$2.97 million||$2.50 million||View||N/A|
|3/6/2014||($0.46)||($0.49)||$2.24 million||$1.90 million||View||N/A|
|11/11/2013||Q3||($0.39)||($0.49)||$2.43 million||$2.20 million||View||N/A|
|8/12/2013||Q2 2013||($0.18)||($0.26)||$2.41 million||$3.72 million||View||N/A|
|5/13/2013||Q113||($0.27)||($0.30)||$2.49 million||$2.70 million||View||N/A|
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Earnings Estimates
2018 EPS Consensus Estimate: ($1.21)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Tetraphase Pharmaceuticals (NASDAQ TTPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 58.50%
Tetraphase Pharmaceuticals (NASDAQ TTPH) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/30/2018||Jacques Dumas||Insider||Sell||8,750||$6.22||$54,425.00||8,750|| |
|1/9/2018||Jacques Dumas||Insider||Sell||7,167||$6.21||$44,507.07|| |
|11/29/2017||L Patrick Gage||Director||Buy||3,880||$6.45||$25,026.00||38,880|| |
|10/31/2017||Jacques Dumas||Insider||Sell||8,750||$6.03||$52,762.50||8,750|| |
|8/22/2017||Jacques Dumas||Insider||Sell||17,500||$6.00||$105,000.00||17,500|| |
|8/17/2017||Jacques Dumas||Insider||Sell||7,155||$5.86||$41,928.30|| |
|3/15/2017||L Patrick Gage||Director||Buy||11,000||$7.49||$82,390.00||35,000|| |
|9/1/2015||Guy Macdonald||insider||Sell||10,000||$41.57||$415,700.00||52,000|| |
|8/14/2015||David Charles Lubner||CFO||Sell||9,500||$42.92||$407,740.00|| |
|8/13/2015||Patrick Taylor Horn||Insider||Sell||10,000||$44.69||$446,900.00|| |
|8/12/2015||L Patrick Gage||Director||Sell||15,000||$45.00||$675,000.00|| |
|7/20/2015||Guy Macdonald||Insider||Sell||15,000||$50.72||$760,800.00|| |
|7/14/2015||David Charles Lubner||CFO||Sell||7,500||$48.92||$366,900.00|| |
|7/13/2015||Patrick Taylor Horn||Insider||Sell||10,000||$48.93||$489,300.00|| |
|7/6/2015||John Craig Thompson||COO||Sell||10,000||$47.91||$479,100.00|| |
|7/1/2015||Guy Macdonald||Insider||Sell||10,000||$47.92||$479,200.00|| |
|6/15/2015||David Charles Lubner||CFO||Sell||17,500||$41.45||$725,375.00|| |
|6/15/2015||John Craig Thompson||COO||Sell||10,000||$41.51||$415,100.00|| |
|6/8/2015||John Craig Thompson||COO||Sell||22,499||$43.26||$973,306.74|| |
|6/1/2015||Guy Macdonald||Insider||Sell||16,087||$41.89||$673,884.43|| |
|5/11/2015||Guy Macdonald||Insider||Sell||20,000||$41.51||$830,200.00|| |
|1/20/2015||Guy Macdonald||Insider||Sell||34,135||$36.59||$1,248,999.65|| |
|10/2/2014||John Gordon Freund||Director||Sell||247,734||$20.88||$5,172,685.92|| |
|10/1/2014||John Gordon Freund||Director||Sell||142,146||$20.84||$2,962,322.64|| |
|9/30/2014||John Gordon Freund||Director||Sell||152,266||$20.18||$3,072,727.88|| |
|9/29/2014||John Gordon Freund||Director||Sell||95,648||$20.19||$1,931,133.12|| |
|9/23/2014||Guy Macdonald||Insider||Sell||10,000||$18.47||$184,700.00|| |
|9/17/2014||Guy Macdonald||Insider||Sell||10,000||$18.00||$180,000.00|| |
|9/17/2014||John Gordon Freund||Director||Sell||144,356||$17.21||$2,484,366.76|| |
|9/12/2014||John Gordon Freund||Director||Sell||55,644||$17.01||$946,504.44|| |
|9/8/2014||John Gordon Freund||Director||Sell||16,700||$15.01||$250,667.00|| |
|9/4/2014||John Gordon Freund||Director||Sell||183,300||$15.05||$2,758,665.00|| |
|9/3/2014||John Gordon Freund||Director||Sell||142,100||$15.04||$2,137,184.00|| |
|8/20/2014||Guy Macdonald||Insider||Sell||10,000||$11.59||$115,900.00|| |
|7/18/2014||Guy Macdonald||Insider||Sell||15,000||$10.61||$159,150.00|| |
|6/23/2014||John Gordon Freund||Director||Sell||47,184||$13.77||$649,723.68|| |
|6/20/2014||John Gordon Freund||Director||Sell||152,816||$13.39||$2,046,206.24|| |
|6/17/2014||David Charles Lubner||CFO||Sell||13,530||$12.51||$169,260.30|| |
|6/17/2014||Guy Macdonald||Insider||Sell||15,000||$12.28||$184,200.00|| |
|5/19/2014||Guy Macdonald||Insider||Sell||15,000||$9.00||$135,000.00|| |
|5/19/2014||Steven Ph.D. Gullans||Director||Buy||25,000||$9.24||$231,000.00||25,000|| |
|5/14/2014||L Patrick Gage||Director||Buy||5,000||$9.25||$46,250.00||5,000|| |
|4/14/2014||Guy Macdonald||Insider||Sell||15,000||$9.69||$145,350.00|| |
|3/20/2014||Joyce Sutcliffe||SVP||Sell||11,494||$12.41||$142,640.54||17,242|| |
|3/6/2014||David Charles Lubner||CFO||Sell||4,510||$13.65||$61,561.50||91,993|| |
|2/20/2014||Joyce Sutcliffe||SVP||Sell||11,494||$14.00||$160,916.00||28,736|| |
|2/12/2014||David Charles Lubner||CFO||Sell||4,506||$13.92||$62,723.52||96,503|| |
|2/7/2014||David Charles Lubner||CFO||Sell||9,928||$14.22||$141,176.16||101,009|| |
|2/5/2014||Joyce Sutcliffe||SVP||Sell||11,494||$13.93||$160,111.42||40,230|| |
|9/18/2013||Ventures Vi Lp Cmea||major shareholder||Sell||100,000||$10.20||$1,020,000.00|| |
|9/17/2013||Ventures Vi Lp Cmea||major shareholder||Sell||53,468||$9.26||$495,113.68|| |
|3/25/2013||John Gordon Freund||Director||Buy||681,012||$7.00||$4,767,084.00|| |
|3/25/2013||Medical Fund Lp Excel||Major Shareholder||Buy||496,121||$7.00||$3,472,847.00|| |
|3/20/2013||Fmr Llc||Insider||Buy||642,857||$7.00||$4,499,999.00|| |
Tetraphase Pharmaceuticals (NASDAQ TTPH) News Headlines
Tetraphase Pharmaceuticals (NASDAQ:TTPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Income Statement, Balance Sheet and Cash Flow Statement
Tetraphase Pharmaceuticals (NASDAQ TTPH) Stock Chart for Tuesday, March, 20, 2018